Search This Blog

Monday, March 16, 2026

Nasus Pharma positive phase 2, pivotal study seen in Q4

 

Nasus Pharma reports positive Phase 2 topline results for intranasal epinephrine NS002 showing faster delivery than EpiPen

  • Company plans to initiate a pivotal study of NS002 in the fourth quarter of 2026.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)